
FDA approves dabrafenib plus trametinib and liquid formulations to treat BRAF V600E low-grade glioma
Pediatric patients with BRAF V600E low-grade glioma as young as 1 year can now be treated with dabrafenib plus trametinib following its FDA approval.





























